Combination of a SARS-CoV-2 IgG Assay and RT-PCR for Improved COVID-19 Diagnosis
1
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background: Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is generally diagnosed by reverse transcription (RT)-PCR or serological assays. The SARS-CoV-2 viral load decreases a few days after symptom onset. Thus, the RT-PCR sensitivity peaks at three days after symptom onset (approximately 80%). We evaluated the performance of the ARCHITECT® SARS-CoV-2 IgG assay (henceforth termed IgG assay; Abbott Laboratories, Lake County, IL, USA), and the combination of RT-PCR and the IgG assay for COVID-19 diagnosis. Methods: In this retrospective study, 206 samples from 70 COVID-19 cases at two hospitals in Tokyo that were positive using RT-PCR were used to analyze the diagnostic sensitivity. RT-PCR-negative (N=166), COVID-19-unrelated (N=418), and Japanese Red Cross Society (N=100) samples were used to evaluate specificity. Results: Sensitivity increased daily after symptom onset and exceeded 84.4% after 10 days. Specificity ranged from 98.2% to 100% for samples from the three case groups. Seroconversion was confirmed from 9 to 20 days after symptom onset in 18 out of 32 COVID-19 cases with multiple samples and from another case with a positive result in the IgG assay for the first available sample. Conclusions: The combination of RT-PCR and IgG assay improves the robustness of laboratory diagnostics by compensating for the limitations of each method.
Abstract
Background: Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is generally diagnosed by reverse transcription (RT)-PCR or serological assays. The SARS-CoV-2 viral load decreases a few days after symptom onset. Thus, the RT-PCR sensitivity peaks at three days after symptom onset (approximately 80%). We evaluated the performance of the ARCHITECT® SARS-CoV-2 IgG assay (henceforth termed IgG assay; Abbott Laboratories, Lake County, IL, USA), and the combination of RT-PCR and the IgG assay for COVID-19 diagnosis. Methods: In this retrospective study, 206 samples from 70 COVID-19 cases at two hospitals in Tokyo that were positive using RT-PCR were used to analyze the diagnostic sensitivity. RT-PCR-negative (N=166), COVID-19-unrelated (N=418), and Japanese Red Cross Society (N=100) samples were used to evaluate specificity. Results: Sensitivity increased daily after symptom onset and exceeded 84.4% after 10 days. Specificity ranged from 98.2% to 100% for samples from the three case groups. Seroconversion was confirmed from 9 to 20 days after symptom onset in 18 out of 32 COVID-19 cases with multiple samples and from another case with a positive result in the IgG assay for the first available sample. Conclusions: The combination of RT-PCR and IgG assay improves the robustness of laboratory diagnostics by compensating for the limitations of each method.
참고문헌 (19)
- Zhu N, "A novel coronavirus from patients with pneumonia in China, 2019", N Engl J Med, 382, pp.727~733 (2020)
- Lauer SA, "The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application", Ann Intern Med, 172, pp.577~582 (2020)
- Guan WJ, "Clinical characteristics of coronavirus disease 2019 in China", N Engl J Med, 382, pp.1708~1720 (2020)
- Wang W, "Detection of SARS-CoV-2 in different types of clinical specimens", JAMA, 323, pp.1843~1844 (2020)
- Sethuraman N, "Interpreting diagnostic tests for SARS-CoV-2", JAMA, 323, pp.2249~2251 (2020)
- Kucirka LM, "Variation in false-negative rate of reverse transcriptase polymerase chain reaction-based SARS-CoV-2 tests by time since exposure", Ann Intern Med, 173, pp.262~267 (2020)
- Li Y, "Stability issues of RT‐PCR testing of SARS‐CoV‐2 for hospitalized patients clinically diagnosed with COVID‐19", J Med Virol, 92, pp.903~908 (2020)
- Xiao AT, "False negative of RT‐PCR and prolonged nucleic acid conversion in COVID‐19: rather than recurrence", J Med Virol, 92, pp.1755~1756 (2020)
- "EUA Authorized Serology Test Performance"[URL]
- Shirato K, "Development of genetic diagnostic methods for novel coronavirus 2019 (nCoV-2019) in Japan", Jpn J Infect Dis, 73, pp.304~307 (2020)
- Nagashima M, "Characteristics of SARS-CoV-2 isolated from asymptomatic carriers in Tokyo", Jpn J Infect Dis, 73, pp.320~322 (2020)
- Bryan A, "Performance characteristics of the Abbott Architect SARS-CoV-2 IgG assay and seroprevalence in Boise, Idaho", J Clin Microbiol, 58, pp.727~728 (2020)
- Theel ES, "Performance characteristics of four high-throughput immunoassays for detection of IgG antibodies against SARS-CoV-2", J Clin Microbiol, 58, pp.e01243-20~ (2020)
- Tang MS, "Clinical performance of two SARS-CoV-2 serologic assays", Clin Chem, 66, pp.1055~1062 (2020)
- Wölfel R, "Virological assessment of hospitalized patients with COVID-2019", Nature, 581, pp.465~469 (2020)
- Carfì A, "Persistent symptoms in patients after acute COVID-19", JAMA, 324, pp.603~605 (2020)
- Imai K, "Clinical evaluation of an immunochromatographic IgM", IgG antibody assay and chest computed tomography for the diagnosis of COVID-19, 2020, pp.128, 104393~
- Takita M, "Geographical profiles of COVID-19 outbreak in Tokyo: an analysis of the primary care clinic-based point-of-care antibody testing", J Prim Care Community Health, 11, pp.2150132720~ (2020)
- Lisboa Bastos M, "Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis", BMJ, 370, pp.m2516~ (2020)